TrialReader

Optimisation of Follicular Recruitment in IVM Cycles

NCT03197077 — Phase 3, Completed, 145 participants, Universitair Ziekenhuis Brussel
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Comparison Between Corifollitropin Alfa and Recombinant FSH for Follicular Recruitment in Women With Polycystic Ovaries Who Undergo IVM Treatment

RegistryNCT03197077, acronym Elonva_IVM
StatusCompleted
PhasePhase 3
Study typeInterventional; randomized, parallel, masking: none, treatment
Enrollment145 (Actual)
SponsorUniversitair Ziekenhuis Brussel (Other); collaborators: Merck Sharp & Dohme LLC
ConditionsInfertility, Female, Polycystic Ovary Syndrome
Interventionsblood sampling, transvaginal ultrasound scanning, oocyte retrieval for IVM, Corifollitropin Alfa, Follitropin beta, oral contraceptive pill pretreatment (Marvelon) (Procedure, drug)
Datesstart 2017-11-01, primary completion 2022-12-31, completion 2022-12-31, first posted 2017-06-23, last updated 2023-04-07
Locations1 site in Belgium

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Infertility, Female All trials for Polycystic Ovary Syndrome All trials of blood sampling All trials of transvaginal ultrasound scanning

-Summary

The study will focus on important aspects related to follicle recruitment using exogenous gonadotropins in patients with polycystic ovaries:

1. Early follicle recruitment in patients with polycystic ovaries using corifollitropin alfa: does administration of this drug result in earlier and higher FSH (follicle stimulating hormone) concentrations above the threshold for follicle recruitment in an IVM (in vitro maturation) cycle preceded by oral contraceptive suppression, in comparison to normal daily administration of rFSH (recombinant follicle stimulating hormone, Puregon)?;
2. The maturation rate of the obtained oocyte-cumulus complexes in standard IVM media registered for clinical use: does stimulation with corifollitropin alfa versus recombinant FSH have an impact on the maturation rate and developmental capacity of the oocytes ?

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
ElonvaExperimentalProcedure: blood sampling; Procedure: transvaginal ultrasound scanning; Procedure: oocyte retrieval for IVM; Drug: Corifollitropin Alfa; Drug: oral contraceptive pill pretreatment (Marvelon)A single injection of 100 microgram corifollitropin alfa. Oocyte retrieval on day five after corifollitropin alfa injection.
PuregonActive comparatorProcedure: blood sampling; Procedure: transvaginal ultrasound scanning; Procedure: oocyte retrieval for IVM; Drug: Follitropin beta; Drug: oral contraceptive pill pretreatment (Marvelon)Three daily injections of 150 IU follitropin beta. Oocyte retrieval on day five after the first follitropin beta injection.
  • blood sampling (Procedure): comparison between corifollitropin alfa and follitropin beta in IVM cycles
  • transvaginal ultrasound scanning (Procedure): comparison between corifollitropin alfa and follitropin beta in IVM cycles
  • oocyte retrieval for IVM (Procedure): comparison between corifollitropin alfa and follitropin beta in IVM cycles
  • Corifollitropin Alfa (Drug): Single injection of 100 micrograms of corifollitropin alfa
  • Follitropin beta (Drug): Daily injection (three days) of follitropin beta
  • oral contraceptive pill pretreatment (Marvelon) (Drug): Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.

+Outcome measures

Primary outcomes

  • Number of COC [5 days after the first gonadotropin injection (on the day of oocyte retrieval)]: Number of oocyte cumulus complexes obtained on the day of oocyte retrieval.

Secondary outcomes

  • Clinical pregnancy rate [At about 6 - 7 weeks gestation]: Clinical pregnancy rate after the first embryo transfer following the IVM cycle

+Eligibility

Sex: Female, ages: 18 Years to 36 Years

Inclusion Criteria:

1. Subfertile patients between 18-36 years old eligible for ART treatment
2. BMI 18-30
3. Polycystic ovaries (PCO) according to the Rotterdam criteria (at least 12 antral follicles per ovary as observed on a baseline ultrasound scan), with or without hyperandrogenism, with or without oligoamenorrhoea. In other words, patients are eligible if they have PCO morphology. A diagnosis of PCOS (polycystic ovary syndrome) based on Rotterdam criteria is not compulsory.

Exclusion Criteria:

1. Antral follicle count (AFC) <24
2. Anti-müllerian hormone (AMH) <3,25 in non-OCP (oral contraceptive pill) users and <4,00 in current OCP users (using Elecsys platform (Roche Diagnostics))
3. Couples requesting PGD (preimplantation genetic diagnosis)
4. Non-obstructive azoospermia in the male partner

+Locations (1)

FacilityCityCountryStatus
UZ BrusselBrusselsBelgium

My Notes